Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 262

1.

Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.

Glassman AH, Bigger JT Jr.

Am J Psychiatry. 2001 Nov;158(11):1774-82. Review.

PMID:
11691681
2.

Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.

Haddad PM, Anderson IM.

Drugs. 2002;62(11):1649-71. Review.

PMID:
12109926
3.
4.

Schizophrenia, antipsychotic drugs, and cardiovascular disease.

Glassman AH.

J Clin Psychiatry. 2005;66 Suppl 6:5-10. Review.

5.

Antipsychotic drugs and QT interval prolongation.

Zareba W, Lin DA.

Psychiatr Q. 2003 Fall;74(3):291-306. Review.

PMID:
12918603
6.

Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death.

Titier K, Girodet PO, Verdoux H, Molimard M, Bégaud B, Haverkamp W, Lader M, Moore N.

Drug Saf. 2005;28(1):35-51. Review.

PMID:
15649104
7.

[Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia].

Gury C, Canceil O, Iaria P.

Encephale. 2000 Nov-Dec;26(6):62-72. Review. French.

PMID:
11217540
8.

QT interval prolongation, torsade de pointes and renal disease.

Patanè S, Marte F, Di Bella G, Currò A, Coglitore S.

Int J Cardiol. 2008 Nov 12;130(2):e71-3. doi: 10.1016/j.ijcard.2007.11.070. Epub 2008 Feb 5.

PMID:
18255176
9.

Investigation of the potential of clozapine to cause torsade de pointes.

Warner B, Hoffmann P.

Adverse Drug React Toxicol Rev. 2002;21(4):189-203. Review.

PMID:
12503253
10.

QT alterations in psychopharmacology: proven candidates and suspects.

Alvarez PA, Pahissa J.

Curr Drug Saf. 2010 Jan;5(1):97-104. Review.

PMID:
20210726
11.

Prolonged QT Risk Assessment in Antipsychotic Overdose Using the QT Nomogram.

Berling I, Isbister GK.

Ann Emerg Med. 2015 Aug;66(2):154-64. doi: 10.1016/j.annemergmed.2014.12.005. Epub 2015 Jan 30.

PMID:
25639523
12.

QTc prolongation by antiepileptic drugs and the risk of torsade de pointes in patients with epilepsy.

Feldman AE, Gidal BE.

Epilepsy Behav. 2013 Mar;26(3):421-6. doi: 10.1016/j.yebeh.2012.09.021. Epub 2012 Dec 4. Review.

PMID:
23218812
13.

Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly.

Vieweg WV, Wood MA, Fernandez A, Beatty-Brooks M, Hasnain M, Pandurangi AK.

Drugs Aging. 2009;26(12):997-1012. doi: 10.2165/11318880-000000000-00000. Review.

PMID:
19929028
14.

[Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].

Ames D, Camm J, Cook P, Falkai P, Gury C, Hurley R, Johnson G, Piepho R, Vieweg V; Cardiac Safety in Schizophrenia Group.

Encephale. 2002 Nov-Dec;28(6 Pt 1):552-62. French.

PMID:
12506268
15.

Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction.

Michalets EL, Smith LK, Van Tassel ED.

Ann Pharmacother. 1998 Jul-Aug;32(7-8):761-5.

PMID:
9681092
16.

Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling?

Vieweg WV, Hasnain M, Howland RH, Hettema JM, Kogut C, Wood MA, Pandurangi AK.

Am J Med. 2012 Sep;125(9):859-68. doi: 10.1016/j.amjmed.2011.12.002. Epub 2012 Jun 27. Review.

PMID:
22748401
17.

Haloperidol-induced torsade de pointes.

O'Brien JM, Rockwood RP, Suh KI.

Ann Pharmacother. 1999 Oct;33(10):1046-50.

PMID:
10534216
18.

Risperidone, QTc interval prolongation, and torsade de pointes: a systematic review of case reports.

Vieweg WV, Hasnain M, Hancox JC, Baranchuk A, Digby GC, Kogut C, Crouse EL, Koneru JN, Deshmukh A, Pandurangi AK.

Psychopharmacology (Berl). 2013 Aug;228(4):515-24. doi: 10.1007/s00213-013-3192-8. Epub 2013 Jun 30. Review.

PMID:
23812796
19.

Tricyclic antidepressants, QT interval prolongation, and torsade de pointes.

Vieweg WV, Wood MA.

Psychosomatics. 2004 Sep-Oct;45(5):371-7.

PMID:
15345781
20.

Risk management of QTc-prolongation in patients receiving haloperidol: an epidemiological study in a University hospital in Belgium.

Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon V.

Int J Clin Pharm. 2016 Apr;38(2):310-20. doi: 10.1007/s11096-015-0242-9. Epub 2016 Jan 9.

PMID:
26749342

Supplemental Content

Support Center